The immunosuppressive drug tacrolimus (TAC) is used clinically to reduce the rejection rate in transplant patients. TAC has contributed to an increased prevalence of cardiovascular disease in patients receiving solid organ transplantation. Mycophenolate mofetil (MMF), a potent inhibitor of de novo purine synthesis, is known to prevent ongoing rejection in combination with TAC. In the present study, we investigated the antioxidant and antigenotoxic effect of MMF on TAC-induced cardiotoxicity in rats. Oral administration of TAC at 2.4, 24, and 60 mg/kg b.w. corresponding, respectively, to 1, 10, and 25% of LD50 for 24 h caused cardiac toxicity in a dose-dependant manner. TAC increased significantly DNA damage level in hearts of treated rats. Furthermore, it increased malondialdehyde (MDA) and protein carbonyl (PC) levels and decreased catalase (CAT) and superoxide dismutase (SOD) activities. The oral administration of MMF at 50 mg/kg b.w. simultaneously with TAC at 60 mg/kg b.w. proved a significant cardiac protection by decreasing DNA damage, MDA, and PC levels, and by increasing the antioxidant activities of CAT and SOD. Thus, our study showed, for the first time, the protective effect of MMF against cardiac toxicity induced by TAC. This protective effect was mediated via an antioxidant process.
BozkayaGNartAUsluAOnmanTAykasADoğanMKaracaB. Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients. Transplant Proc2008; 40: 151–5.
2.
RedmonJBOlsonLKArmstrongMBGreeneMJRobertsonRP. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest1996; 15;98: 2786–93.
3.
ClipstoneNACrabtreeGR. Calcineurin is a key signaling enzyme in T-lymphocyte activation and the target of the immunosuppressive drugs cyclosporine A and FK506. Nature1992; 357: 695–7.
4.
GummertJFIkonenTMorrisRE. Newer immunosuppressive drugs. Am Soc Nephrol1999; 10: 1366–80.
5.
AtkisonPJoubertGBarronAGrantDWallWRosenbergHHowardJWilliamsSStillerCParadisKSeidmanE. Hypertrophic cardiomyopathy associated with tacrolimus in pediatric transplant patients. Lancet1995; 345: 894–6.
6.
SawabeTMizunoSGondoHMaruyamaTNihoY. Sinus arrest during tacrolimus (FK506) and digitalis treatment in a bone marrow transplant recipient. Transplant1997; 64: 182–3.
7.
HodakSPMoubarakJBRodriguezIGelfandMCAlijaniMRTracyCM. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. Transplant1998; 66: 535–7.
8.
TakedaYMiyamoriIFurukawaKInabaSMabuchiH. Mechanisms of FK 506-induced hypertension in the rat. Hypertension1999; 33: 130–6.
9.
MillerLW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant2002; 2: 807–18.
10.
LindenfeldJMillerGGShakarSFZoltyRLowesBDWolfelEEMestroniLPageRL2ndKobashigawaJ. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation2004; 110: 3858–65.
11.
MoralesJMDomínguez-GilB. Impact of tacrolimus and mycophenolate mofetil combination on cardiovascular risk profile after kidney transplantation. J Am Soc Nephrol2006; 17: S296–303.
12.
JeongHJKimYSHongIC. Vascular endothelin, TGFbeta, and PDGF expression in FK506 nephrotoxicity of rats. Transplant Proc1998; 30: 3596–7.
13.
KhannaAKPieperGM. NADPH oxidase subunits (NOX-1, p22phox, Rac-1) and tacrolimus-induced nephrotoxicity in a rat renal transplant model. Nephrol Dial Transplant2007; 22: 376–85.
14.
Al-HarbiNOImamFNadeemAAl-HarbiMMIqbalMRahmanSAl-HosainiKABahashwanS. Protection against tacrolimus-induced cardiotoxicity in rats by olmesartan and aliskiren. Toxicol Mech Methods2014; 9: 1–23.
15.
AgirbasliMPapila-TopalNOgutmenBDenizHCakalagaogluFTuglularSAkogluE. The blockade of the renin-angiotensin system reverses tacrolimus related cardiovascular toxicity at the histopathological level. J Renin Angiotensin Aldosterone Syst2007; 8: 54–8.
16.
GallagherHAndrewsP.A. Cytomegalovirus infection and abdominal pain with mycophenolate mofetil is there a link?Drug Saf2001; 24: 405–12.
17.
AllisonACEuguiEM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant1996; 10: 77–84.
18.
HalloranPMathewTTomlanovichSGrothCHooftmanLBarkerC. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplant1997; 63: 39–47.
19.
Meier-KriescheHULiSGruessnerRWFungJJBustamiRTBarrMLLeichtmanAB. Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant2006; 6: 1111–31.
20.
BoudjemaKCamusCSalibaFCalmusYSalaméEPageauxGDucerfCDuvouxCMouchelCRenaultACompagnonPLorhoRBellissantE. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant2011; 11: 965–76.
21.
Dall'EraM. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol2011; 23: 454–8.
22.
KoehlGEWagnerFStoeltzingOLangSASteinbauerMSchlittHJGeisslerEK. Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability. Transplant2007; 83: 607–14.
23.
MoralesJMDominguez-GilB. Cardiovascular risk profile with the new immunosuppressive combinations after renal transplantation. J Hypertens2005; 23: 1609–16.
24.
GreensteinSMSunSCalderonTMKimDYSchreiberTCSchechnerRSTellisVABermanJW. Mycophenolate mofetil treatment reduces atherosclerosis in the cholesterol-fed rabbit. J Surg Res2000; 91: 123–9.
25.
RandhawaMA. Calculation of LD50 values from the method of Miller and Tainter 1944. J Ayub Med Coll Abbottabad2009; 21: 184–5.
26.
BradfordMM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem1976; 72: 248–54.
27.
TiceRRAgurellEAndersonDBurlinsonBHartmannAKobayashiHMiyamaeYRojasERyuJCSasakiYF. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen2000; 35: 206–21.
28.
PicadaJNFloresDGZettlerCGMarroniNPRoeslerRHenriquesJA. DNA damage in brain cells of mice treated with an oxidized form of apomorphine. Mol Brain Res2003; 114: 80–5.
29.
CollinsARDusinskaMGedikCMStetinaR. Oxidative damage to DNA: Do we have a reliable biomarker? Environ. Health Perspect1996; 104: 465–9.
30.
AustSD. Metal ions, oxygen radicals and tissue damage. Bibl Nutr Dieta1989; 43: 266–77..
31.
MercierYGatellierPRenerreM. Lipid and protein oxidation in vitro, and antioxidant potential in meat from Charolais cows finished on pasture or mixed diet. Meat Sci2004; 66: 467–73..
32.
ClairborneACatalase activity. In: GreenwaldRA (ed). Handbook of Methods for Oxygen Radical Research, Boca Raton, FL: CRC Press, 1985, pp. 283–4.
33.
BeyerWEFridovichI. Assaying for superoxide dismutase activity: some large consequences of minor changes in conditions. Anal Biochem1987; 161: 559–66.
34.
HarrisonDGriendlingKKLandmesserUHornigBDrexlerH. Role of oxidative stress in atherosclerosis. Am J Cardiol2003; 91: 7 A–11 A.
35.
VassalleCPetrozziLBottoNAndreassiMGZucchelliGC. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med2004; 256: 308–15.
36.
SchramaYCJolesJAvan TolABoerPKoomansHAHeneRJ. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. Transplant2000; 69: 376–83.
37.
SinghNPMcCoyMTTiceRRSchneiderEL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res1988; 175: 184–91.
38.
HanSYMunKCChoiHJKwakCSBaeJHSuhSIParkSBKimHCChangEJ. Effects of cyclosporine and tacrolimus on the oxidative stress in cultured mesangial cells. Transplant Proc2006; 38: 2240–41.
39.
BravoYQuirozYFerrebuzAVaziriNDRodríguez-IturbeB. Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am J Physiol Renal Physiol2007; 29: F616–23.
40.
AraCDiricanAUnalBBay KarabulutAPiskinT. The effect of melatonin against FK506-induced renal oxidative stress in rats. Surg Innov2011; 18: 34–8.
41.
KidokoroKSatohMNagasuHSakutaTKuwabaraAYorimitsuDNishiYTomitaNSasakiTKashiharaN. Tacrolimus induces glomerular injury via endothelial dysfunction caused by reactive oxygen species and inflammatory change. Kidney Blood Press Res2012; 35: 549–57.
42.
KrötzFKellerMDerflingerSSchmidHGloeTBassermannFDuysterJCohenCDSchuhmannCKlaussVPohlUStempfleHUSohnHY. Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and superoxide formation by a Rac1-dependent mechanism. Hypertension2007; 491: 201–8.
43.
HuangQZhouHJZhangH1HuangYHinojosa-KirschenbaumFFanPYaoLBelardinelliLTellidesGGiordanoFJBudasGRMinW. Thioredoxin-2 Inhibits Mitochondrial ROS Generation and ASK1 Activity to Maintain Cardiac Function. Circulation2015; 131: 1082–97.
44.
YangSGYaoZQLiMYouRSWangAHZhaoHJ. Correlation between left ventricular mass index and NADPH oxidase p22phox in patients with non-valvular chronic heart failure. Nan Fang Yi Ke Da Xue Xue Bao2015; 35: 142–4.
45.
BrionesAMTouyzRM. Oxidative stress and hypertension: current concepts. Curr Hypertens Rep2010; 12: 135–42.
46.
Fréguin-BouillandCGodinMBellienJRichardVRemy-JouetIDautreauxBHenryJPCompagnonPThuillezCPlissonnierDJoannidèsR. Protective effect of mycophenolate mofetil on endothelial function in an aortic allograft model. Transplant2011; 91: 35–41.
47.
Rodriguez-IturbeBPonsHQuirozYGordonKRinconJChavezMParraGHerrera-AcostaJGomez-GarreDLargoREgidoJJohnsonRJ. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int2001; 59: 2222–2232.
48.
HerreraJFerrebuzAGarcıa MacGregorEGRodrıguez-IturbeB. Mycophenolate mofetil improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol2006; 17: S218–25.
